- Home
- BBUC vs AKRO Comparison
BBUC vs AKRO Comparison
Compare BBUC & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BBUC
- AKRO
- Stock Information
- Founded
- BBUC 2022
- AKRO 2017
- Country
- BBUC United States
- AKRO United States
- Employees
- BBUC N/A
- AKRO N/A
- Industry
- BBUC
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- BBUC
- AKRO Health Care
- Exchange
- BBUC Nasdaq
- AKRO Nasdaq
- Market Cap
- BBUC 1.9B
- AKRO 1.8B
- IPO Year
- BBUC N/A
- AKRO 2019
- Fundamental
- Price
- BBUC $23.63
- AKRO $56.12
- Analyst Decision
- BBUC
- AKRO Strong Buy
- Analyst Count
- BBUC 0
- AKRO 9
- Target Price
- BBUC N/A
- AKRO $75.86
- AVG Volume (30 Days)
- BBUC 53.0K
- AKRO 2.1M
- Earning Date
- BBUC 01-01-0001
- AKRO 02-27-2025
- Dividend Yield
- BBUC 1.07%
- AKRO N/A
- EPS Growth
- BBUC N/A
- AKRO N/A
- EPS
- BBUC N/A
- AKRO N/A
- Revenue
- BBUC $8,208,000,000.00
- AKRO N/A
- Revenue This Year
- BBUC N/A
- AKRO N/A
- Revenue Next Year
- BBUC N/A
- AKRO N/A
- P/E Ratio
- BBUC N/A
- AKRO N/A
- Revenue Growth
- BBUC 6.83
- AKRO N/A
- 52 Week Low
- BBUC $18.21
- AKRO $15.32
- 52 Week High
- BBUC $28.29
- AKRO $58.40
- Technical
- Relative Strength Index (RSI)
- BBUC 41.90
- AKRO 82.26
- Support Level
- BBUC $23.38
- AKRO $24.69
- Resistance Level
- BBUC $24.41
- AKRO $57.51
- Average True Range (ATR)
- BBUC 0.66
- AKRO 2.92
- MACD
- BBUC 0.07
- AKRO 3.34
- Stochastic Oscillator
- BBUC 33.33
- AKRO 87.72
About BBUC Brookfield Business Corporation Exchangeable Subordinate Voting Shares
Brookfield Business Corp is a company established as a vehicle that owns and operates certain services and industrial operations on a global basis and an alternative vehicle for investors who prefer investing in its operations through a corporate structure. Its goal is to generate returns through long-term capital appreciation with a modest distribution yield.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.